

1 **Title:** Online Personal Training in Patients with Marfan Syndrome: A Randomized
2 Controlled Study of its Impact on Quality of Life and Physical Capacity

3

4 Steeve Jouini¹, PhD, Olivier Milleron^{2,3}, MD, Ludivine Eliahou^{2,3}, MD, Guillaume
5 Jondeau^{2,3,4}, MD, PhD, Damien Vitiello^{1*}, PhD.

6

7 1. Université Paris Cité, URP 3625-Institut des Sciences du Sport Santé de Paris (I3SP),
8 75015 Paris, France.

9 2. Centre national de référence pour le syndrome de Marfan et pathologies apparentés,
10 Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.

11 3. Service de Cardiologie, Centre National de Référence Pour le Syndrome de Marfan et
12 Apparentés, AP-HP, Hôpital Bichat, 75018 Paris, France.

13 4. Université Paris Cité, Laboratory for Vascular Translational Science, INSERM U1148,
14 Hôpital Bichat-Claude-Bernard, Paris, France.

15

16 Brief title : Training in Marfan Syndrome

17

18 * *Address for correspondence:*

19 Damien VITIELLO, Université Paris Cité, URP 3625- Institut des Sciences du Sport Santé de
20 Paris (I3SP), School of Sport Sciences (STAPS), F-75015 Paris, France. Email:
21 damien.vitiello@u-paris.fr. Tel: 0033176533402.

22

23 Total word count of the manuscript: introduction to the reference 3702 words

24

25

26 **Abstract**

27 Background: Marfan syndrome (MFS) is a rare genetic disorder affecting the vascular and
28 musculoskeletal systems. Exercise is classically contraindicated and there are no data on the
29 limitations associated with the syndrome and the benefits of training in this population. This
30 study aimed to characterise the quality of life (QoL) and physical capacity of patients with
31 MFS and to evaluate the benefits of a 3-month online personal training program.

32 Methods: MFS patients were compared with healthy subjects (H-S) at baseline. They were
33 then randomized 1:1 into a training group (MFS-T) and a control group (MFS-C). The
34 training consisted of 2 supervised online training sessions per week at home for 3 months, and
35 the session program was selected based on the initial assessment. The main outcome measure
36 was QoL as assessed by the MOS SF-36. The evolution of parameters during training was
37 compared between MFS-T and MFS-C.

38 Results: At baseline, QoL in all dimensions was lower in MFS. Peak oxygen uptake
39 ($V\dot{O}_{2peak}$) was also 25% lower, as was muscle elasticity. Training significantly improved
40 1) QoL (+20.2±14.3 MFS-T vs. 0.7±0.5 MFS-C), 2) $V\dot{O}_{2peak}$ (+34% MFS-T vs. 14% MFS-
41 C), 3) muscle elasticity index (11.5±8.2 MFS-T vs. +1.2±1.7 MFS-C), reduced blood
42 pressures during isometric squat (systolic -19±30 MFS-T vs. 0±6 MFS-C; diastolic -27±39
43 MFS-T vs. +2±15 MFS-C), reduced pulse wave velocity (PWV) at rest (-1.20±1.89 MFS-T
44 vs. -0.40±1.61 MFS-C) and after peak exercise (-0.42±0.45 MFS-T vs. 0.08±0.48 MFS-C).
45 Aorta diameter remained stable in both groups (MFS-T -0.19±1.1 vs. 0.11±0.78 MFS-C).
46 After training, QoL remained lower in MFS-T than in H-S, but peak $V\dot{O}_2$, PWV at rest and
47 after exercise were similar to those of H-S.

48 Conclusions: A 3-month online training program had a beneficial effect on QoL,
49 cardiovascular and muscular parameters in MFS without affecting aortic root diameter.

50

51 **Keywords:** Marfan Syndrome, personalized training, exercise, e-rehabilitation.

52 *Non-standard abbreviations and acronyms*

53 1RM: One repetition maximum
54 MFS: Marfan syndrome
55 FBN1: Fibrillin-1
56 MFS-C: Marfan syndrome control
57 MFS-T: Marfan syndrome training
58 H-S: Healthy subjects
59 FB: Fat body
60 MM: Mass muscular
61 BMI: Body mass index
62 EF: Ejection fraction
63 LV: Left ventricle
64 GLS: Global longitudinal strain
65 RV: Right ventricle
66 PWV: Pulse wave velocity
67 OUES: Oxygen uptake efficiency slope
68 $\dot{V}O_{2peak}$: Peak oxygen uptake
69 VT1: First ventilatory threshold
70 VE: Minute ventilation
71 $\dot{V}CO_2$: Volume of CO₂ produced per minute
72 VE/ $\dot{V}CO_2$: Ventilation/carbon dioxide output ratio
73 FEV1: Forced expiratory volume in one second
74 mET: Muscular exercise testing
75 HR: Heart rate
76 SBP: Systolic blood pressure
77 DBP: Diastolic blood pressure
78 CPET: Cardiopulmonary exercise testing
79 Aix: Augmentation index
80 TGF-B: Transforming growth factor beta
81 TIMP: Tissue inhibitors of metalloproteinases
82 MMPs: Matrix metalloproteinases
83 QoL: Quality of life
84
85

86 **Introduction**

87 Marfan syndrome (MFS) is an autosomal dominant genetic disorder caused by a pathogenic
88 variant in the gene encoding fibrillin 1 (*FBNI*), with more than 1,300 unique pathogenic
89 variants reported. MFS affects multiple systems, including the cardiovascular and
90 musculoskeletal systems¹⁻⁴ and is associated with altered quality of life (QoL)⁵. The fatal
91 risk associated with MFS is related to aortic aneurysm expansion leading to aortic dissection
92 which can be prevented by prophylactic surgery. To date, the main medical therapy to reduce
93 the cardiovascular impact of MFS is the use of betablockers and regular medical follow-up⁶.
94 There is currently no specific exercise program available and validated, and recommendations
95 still limit physical activity to minimize the risk of aortic dilation, dissection, and possible
96 aortic rupture⁶.

97

98 The benefits of cardiopulmonary exercise training are well documented in the general
99 population and its importance is increasingly being emphasised in patients with various
100 cardiovascular diseases, including chronic coronary heart disease^{7,8} and heart failure⁹.
101 However, there is a lack of clear data in patients with MFS. In fact, patients with MFS may
102 differ from other populations because MFS has been associated with a specific myopathy¹⁰
103 and there is concern that increasing the blood pressure (BP) during exercise may increase
104 aortic root dilatation and the risk of aortic dissection. Indeed, aortic dissection has been
105 reported following isometric exercise. Deconditioning may result from this concern and may
106 also contribute to the alteration in exercise capacity and QoL in patients with MFS.

107 In addition, recent animal studies suggest that regular endurance exercise may be beneficial
108 ^{11,12}. Therefore, a personalised online training program in combination with standard care may
109 be beneficial in patients with MFS¹³.

110 To our knowledge, there are currently no randomized and controlled trials evaluating the
111 effects of such a program in patients with MFS and no data on the physical and physiological
112 capacity of these patients. Therefore, the aim of this study was to evaluate the effects of a 3-
113 month personalised e-training program on QoL, cardiovascular and muscular capacity in adult
114 patients with MFS. The results of this study may provide new insights into the management of
115 MFS patients and contribute to the development of more effective treatment strategies.

116

117 **Method**

118

119 *Study population*

120 MFS patients: Inclusion criteria for MFS patients were: 1) adult patients (18 to 75 years of
121 age); 2) presence of an FBN1 pathogenic variant; 3) ability to exercise; and 4) having health
122 insurance. Exclusion criteria for MFS patients were: patients with cardiovascular disease
123 unrelated to MFS, pregnant patients, history of aortic dissection, aortic diameter > 45 mm,
124 significant aortic regurgitation, uncontrolled resting hypertension (diastolic blood pressure >
125 90 mmHg and systolic blood pressure > 140 mmHg), unavailability by telephone,
126 participation in an experiment in the 3 months prior to screening, unwillingness or inability to
127 sign the informed consent form.

128 Healthy subjects were matched for age and sex.

129

130 *Study Design*

131 MFS patients were randomized 1/1 into 2 groups: 1) MFS-C who did not benefit from the
132 training program and were assessed at baseline and after 3 months; 2) MFS-T who followed
133 the personalised e-training program for 3 months and were assessed at baseline and after 3
134 months of training.

135 All participants gave written informed consent before enrolment. The study complied with the
136 Declaration of Helsinki, the institutional ethics committee approved the study protocol
137 (#2020-A01751-38) and the French Society of Cardiology promoted the study.

138 It has been approved by Protection of Persons Committee SOUTH MEDITERRANEAN
139 CHU CIMIEZ HOSPITAL CS 91179 06003 NICE CEDEX 1.

140 The trial was prospectively registered at Clinical Trial NCT04553094

141

142 **Evaluation of patients**

143

144 *Quality of life assessment*

145 The Medical Outcome Study Short Form - 36 (MOS SF-36) was used to assess QoL.¹⁴

146

147 *Echocardiography*

148 Patients with MFS underwent standard echocardiography and tissue Doppler imaging (Vivid
149 9 Dimension® ultrasound device - GE Healthcare). This study included calculation of left
150 ventricular ejection fraction (LVEF), calculation of E/A ratio. Aortic diameters were
151 measured at different levels (*i.e.*, ring, root, tubular aorta, arch, descending thoracic aorta and
152 abdominal aorta). 2D strain echocardiography was also performed to assess global systolic
153 longitudinal strain (GLS) of the LV and right ventricle (RV).

154

155 *Body composition*

156 Body composition was measured using a bioimpedance scale (Tanita Body Composition
157 Analyzer BC-420MA). Body weight and percentage of fat mass (BF%), muscle mass (MM%)
158 and water were assessed. Body mass index (BMI) was calculated using the following formula
159 $BMI = kg / m^2$, where kg is the body weight in kilograms and m² is the height in metres
160 squared.

161

162 ***Cardiopulmonary exercise training (CPET) and spirometry***

163 At rest, before exercise, an electrocardiogram (ECG) was taken (200S-Cardioline), SBP and
164 DBP were measured with an automatic tensiometer (METRONIK BL-6 1000) and pulse wave
165 velocity (PWV) was measured with a Popmètre®.

166 The patients then performed an incremental exercise on the ergocycle to assess their
167 cardiorespiratory capacity. The intensity of the exercise gradually increased by 10 W/min
168 until the patients voluntarily stopped. During the exercise, the patients' expired gases were
169 continuously analysed. Peak oxygen uptake ($\dot{V}O_{2peak}$) was determined as the highest value
170 achieved during exercise. The ventilatory threshold 1 (VT1), the oxygen uptake efficiency
171 slope (OUES), the ratio of ventilation (VE) to carbon dioxide production ($\dot{V}CO_2$) ($VE/\dot{V}CO_2$)
172 were calculated. Pulse wave velocity (PWV) was measured after the first ventilator
173 threshold. Heart rate (HR) and SBP And DBP were measured every 3 minutes, during the
174 CPET. If the SBP > 160 mmHg during the exercise (*i.e.*, CPET), the patient with MFS was
175 excluded from the study¹⁵⁻¹⁸.

176 Pulse wave velocity (PWV) was measured again after exercise.

177 HR at the first ventilatory threshold (VT1) (HRVT1) and HR at $\dot{V}O_{2peak}$ (HRpeak $\dot{V}O_2$)
178 were recorded to adapt and personalise the training loads for the 3-month e-training program.

179 Peak and training HR were determined during CPET.

180 Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and peak
181 expiratory flow 25-75% (PEF25-75) were measured and FEV1/FVC was calculated.

182

183 ***Muscular exercise testing (mET)***

184 Lower limb muscle strength and maximal force contraction were measured during a
185 countermovement jump (cm), a squat jump (cm) and a one repetition maximum (1RM) based
186 on 3 consecutive squats using a linear encoder (Bosco System Platform Chronojump).

187 They then performed an isometric bodyweight squat. During the squat, blood pressure and
188 PWV were measured (Detailed Appendix 1).

189 Two vertical jump tests were performed: the countermovement jump (CMJ) and the squat
190 jump (SJ) using the Chronojump platform. The recovery value is the difference measured
191 between the heights of the two jumps.

192

193 ***Pulse wave analysis***

194 Pulse wave analysis was performed at rest, during exercise (*i.e.*, isometric squat and CPET)
195 and after exercise. Complete pulse wave analysis included cardiac index, reflection
196 coefficient, PWV, AIx, SBP and DBP.

197 - At rest before the exercise test. A comprehensive analysis was first performed at rest in
198 the supine position. The average of the three consecutive results obtained was used for
199 analysis.

200 - During the squat. Pulse wave velocity (PWV), systolic blood pressure (SBP) and
201 diastolic blood pressure (DBP) were then measured during the 'isometric squat' while
202 the patients were squatting with their knees bent at 90°, positioned on a step with their
203 toes halfway over the edge of the step. One sensor was placed on the second toe and
204 the other on the middle finger of the hand, while the cuff was placed on the left arm.
205 Only one assessment of arterial pressure was performed and PWV was measured
206 (PWV was continuously monitored).

207 - At rest after the CPET exercise test. Finally, the complete analysis was repeated at rest
208 in the supine position after the CPET (average of 3 measurements).

209

210 *3-month personalized online training program for Marfan patients*

211 The MFS patients in the MFS-T group completed the personalised 3-month e-training
212 program at home. The program consisted of 2 training sessions per week for a total of 24
213 sessions. The initial exercise intensity during the training sessions was chosen based on
214 HRVT1 and the HR peak achieved during CPET. The patient had to remain within this
215 intensity range.

216 Details of the training method and evaluations are described in Appendices 1 and 2. HR, DBP
217 and SBP were telemonitored during each training session and followed live either by
218 videoconference and/or by connected devices. This made it possible to check that patients
219 were achieving the target HR and to verify that SBP did not exceed 160 mmHg. Training
220 loads were adjusted weekly to achieve the best training effect based on heart rate and the RPE
221 (rate of perceived exertion) scale^{19,20}. Finally, patients were frequently reminded of the
222 training program, 3 to 4 training sessions in advance, in order to increase their adherence to
223 the program.

224

225 *Statistical analyses*

226 The study used 1:1 randomisation to form treatment and control groups to minimise potential
227 selection bias and maximise statistical power. The sample size was determined based on the
228 study objectives using 80% power and a 5% significance level. A mean difference of 13
229 points in QoL (physical component) with a standard deviation of 20 was estimated between
230 the trained group and the control group. The minimum number of subjects required in each
231 group was 38, but to allow for a 20% drop-out rate, the number of patients in each group was
232 increased to 46.

233 Statistical analyses were performed using GraphPad Prism 9.4.1 software (San Diego, CA,
234 USA). One-way ANOVA was used to compare the different groups (H-S, MFS-C, MFS-T) in
235 the pre- and post-training sessions. Two-way repeated measures ANOVAs were used to
236 identify pre-post differences in the MFS-C and MFS-T groups. Different models (*i.e.*, time,
237 group and group x time interaction) were used. When significant interactions were found,
238 Tukey's post hoc test was used. To compare the effect of training on the MFS-C and MFS-T
239 groups, we analysed the difference after 3 months - baseline and used a Student's t-test. Data
240 were presented as percentages (%) or mean \pm standard deviation. Statistical significance was
241 considered when P values were ≤ 0.05 .

242

243 **Results**

244 A total of 105 subjects were recruited for the study (Figure 1). There were 70 MFS patients
245 and 35 healthy subjects. The characteristics of the participants are shown in Table 1. The H-S
246 were sex and age matched to the MFS patients, all of whom were receiving beta-blockers.
247 The MFS patients were heavier and taller than the H-S. Almost half of the MFS patients had
248 scoliosis and 61% had ankle sprains. The MFS patients also had dilation of the aorta and
249 global joint hypermobility.

250

251 ***Baseline : Comparison of MFS patients with matched controls***

252 QoL (Table 2) was significantly different between MFS and H-S in all eight dimensions
253 assessed ($P < 0.05$). Physical function, the criterion used to calculate the power of the study,
254 was 55% and 68.97% lower in MFS-C and MFS-T, respectively, compared to H-S.

255 $\dot{V}\square\text{O}_2$ peak was 25% lower in MFS (MFS-C and MFS-T) compared to H-S (Figure 2a). PWV
256 was significantly higher in MFS immediately after CPET (Figure 2b), ($P < 0.001$). SBP and
257 DBP were significantly higher in MFS than in H-S during isometric squat (+13% and +44%
258 respectively; Figure 2c).

259 The 1RM values were significantly lower in MFS patients compared to H-S ($p < 0.001$)
260 (Figure 3a).

261 The aortic root diameter was similar in the MFS-C and MFS-T groups (38.1 ± 4.1 mm vs.
262 38.7 ± 4.6 mm, NS) and did not increase after training (Figure 2d).

263

264 ***Characteristics of training sessions***

265 The duration of the training session, peak and mean heart rate during the training session,
266 perceived exertion during the training session and blood pressure at the beginning, middle and
267 end of the training session were recorded and are shown in Table 3.

268

269 ***Main effects of a 3-month personalized online training program in MFS patients: Δ : post -*** 270 ***pre***

271 All dimensions of QOL improved significantly more in the MFS-T group than in the MFS-C
272 group after training (Table 2). The main criterion, physical function, increased by 33% in the
273 MFS-T group but remained significantly lower than in the H-S group ($P < 0.0001$). In
274 addition, a significant 31% reduction in pain was observed in the MFS-T group ($P < 0.0001$).

275 $\dot{V}O_{2peak}$ increased significantly more in the MFS-T group than in the MFS-C group ($P < 0.05$)
276 (Figure 2a). Actually, after training, $\dot{V}O_{2peak}$ in MFS-T group was not significantly different
277 from $\dot{V}O_{2peak}$ in H-S ($P = 0.057$). (26.5 ± 4.8 ml.min⁻¹.kg⁻¹ vs. 29.4 ± 7.6 ml.min⁻¹.kg⁻¹, NS).

278 PWV immediately after CPET decreased significantly more in the MFS-T group than in the
279 MFS-C group (5.24 ± 0.9 m/s-1 vs. 5.69 ± 0.74 m/s-1, $P < 0.0001$) (Figure 2b). In fact, the post-
280 training PWV in the MFS-T group was close to the PWV in the H-S group (5.24 ± 0.74 m.s-1
281 MFS-T vs. 4.65 ± 0.73 m.s-1 H-S, NS).

282 1 RM increased significantly more in MFS-T than in MFS-C (+17 kg vs. +9 kg, $P < 0.001$)
283 (Figure 3a) although it remained significantly lower than in H-S (81.9 ± 21.9 kg vs. 133 ± 77 kg,

284 P<0.05). The Elasticity Index increased significantly more in the MFS-T than in the MFS-C
285 (+9.09±1.46 cm MFS-T vs. 0.03±1.45 cm MFS-C, P < 0.001) (Figure 3b).

286

287 Blood pressure decreased significantly more in the MFS-T than in the MFS-C during
288 isometric squat exercise (sBP -19±30 MFS-T vs. 0±6 MFS-C; dBp -27±39 MFS-T vs. +2±15
289 MFS-C; P < 0.02). SBP and dBp were lower after training in the MFS-T group than in the
290 MFS-C group (sBP: 148±15 mmHg MFS-T vs. 162±18 mmHg MFS-C, P < 0.05; dBp: 94±8
291 mmHg±18 mmHg MFS-T vs. 113±20 mmHg MFS-C, P < 0.001) (Figure 2c). In the MFS-T
292 group, sBP after training was similar to that in the H-S group (148±11 mmHg vs. 143±16
293 mmHg, NS), but dBp tended to be higher (94±8 mmHg±7.37 mmHg vs. 78±14 mmHg, NS).

294 Aortic root diameters remained stable and were similar in MFS-T and MFS-C after training
295 (38.1±4.1 mm vs. 39.1±4.4 mm, NS; Figure 2d). In fact, during training, aortic diameter
296 tended to decrease in MFS-T and increase in MFS-C, but this difference was not statistically
297 significant (0.11±0.78 vs. -0.19±1.12 mm; p=0.74) (Figure 2d).

298

299 ***Cardiovascular and respiratory effects of a 3-month personalized e-training program in***
300 ***MFS patients***

301 The e-training program reduced the Aix and the reflection coefficient and increased the
302 elasticity index in the MFS-T group compared to the MFS-C group (Table 4). It also reduced
303 PWV at rest, during a squat and after CPET in the MFS-T group compared to the MFS-C
304 group. The reduction in SBP with training was greater in the MFS-T group compared to the
305 MFS-C group at rest, during a squat and during the recovery period immediately after CPET,
306 but not during CPET. Finally, no significant differences in Tiffeneau index and PEF 25-75
307 were found between MFS-C and MFS-T after the exercise program.

308

309 ***Dropout rates***

310 The overall dropout rate was 25%. However, it was lower in the MFS-T group (17%) than in
311 the MFS-C group (42%) (Figure 1).

312

313

314

315 **Discussion**

316 In this randomized and controlled study, we show that 3 months of personalised home-
317 based training significantly restores the QoL of MFS patients, in particular the main criterion
318 "physical function", increases exercise capacity as measured by $V\dot{O}_2$ peak and muscle
319 strength as measured by 1RM, and improves arterial compliance as shown by a decrease in
320 PWV. These changes can be attributed to the training program we proposed to our patient,
321 thanks to the randomized control design of our study, which made it possible to compare the
322 evolution of each parameter after the 3-month period in the 2 groups (control group, without
323 training, called MFS-C, and training group, called MFS-T). The results indicate a beneficial
324 cardiopulmonary, muscular and vascular effect of training in this population. In addition,
325 training reduced resting and exercise sBP and dBP, which may also be beneficial in the long
326 term, and no detrimental effect on aortic root diameter was observed.

327 In our program, each exercise session was individualised based on the CEPT at
328 baseline. The intensity of the exercise was chosen to keep the heart rate above the heart rate
329 observed at the first ventilator threshold during CPET and below the peak heart rate observed
330 during CPET. The first training session was conducted in the hospital under medical
331 supervision to monitor blood pressure and heart rate during the exercises proposed for the
332 training sessions. All subsequent sessions were carried out at home. During the course of the
333 program, the intensity of the home training sessions was adjusted on the basis of the perceived

334 exertion scale and the heart rate recorded by the patient during the previous training session.
335 This allowed for a personalised home-based program with maximum safety and efficiency.

336 To our knowledge, there is only one study of exercise training in people with MFS¹⁵.
337 In this observational study of a 3-week low-intensity exercise program in 18 MFS patients,
338 the authors reported positive effects on mental health, fatigue and exercise capacity. The
339 effect on aortic root diameter was not reported in this paper. However, a beneficial effect on
340 the aortic root has been suggested in MFS mice^{11,12}: in this mouse model, moderate-intensity
341 exercise reduced the growth rate of aortic diameter and the risk of aortic rupture in exercised
342 mice compared with their sedentary counterparts. These protective effects were achieved with
343 exercise at intensities between 55 and 65% of $\dot{V}\square O_{2peak}$.

344 Changes in QoL in patients with Marfan syndrome have been reported previously^{21,22}.
345 However, no intervention has been shown to improve QoL in this population. The beneficial
346 effects of exercise training on QoL in patients with cardiovascular disease have been well
347 documented^{23,24}, but data on the effects of training in patients with MFS are scarce. We show
348 that exercise improves all dimensions of QoL (Table 4). The dropout rate may also indirectly
349 reflect the perceived benefit of the training program by patients: in our study, the dropout rate
350 was much higher in the control group than in the training group (42% vs. 17%). Training may
351 become an important tool to limit the decline in QoL previously reported in the MFS
352 population²².

353 The functional limitation of MFS patients is evidenced by the 25% lower $\dot{V}O_{2peak,at}$
354 baseline when compared to healthy subjects. This result is in keeping with two previous small
355 studies^{25,26}, and may partly explain the altered QoL in this population. Betablockade may
356 participate in this decreased peak $\dot{V}\square O_2$, as all MFS patients were receiving this therapy: in
357 normal subjects²⁷, betablockade has been associated with decreased peak $\dot{V}\square O_2$ by 5 to 15%,
358 and therefore it is unlikely that betablockade does account for the entire difference between

359 healthy subjects and MFS patients. Beyond $\dot{V}\dot{O}_2$, a number of parameters are altered in this
360 population, such as maximal strength and elasticity index in the muscular component of the
361 lower limbs (already reported by 2 previous studies^{25,26}) which may also participate in the
362 altered QoL.

363 The training program may be beneficial beyond the increase in peak $\dot{V}\dot{O}_2$ and
364 improved QoL: the training program increased pulmonary parameters such as Tiffeneau index
365 and PEF25-75%, which increased to values similar to those of healthy subjects (Table 3). The
366 3 muscle components were also increased: 1/ increase in muscle mass, 2/ increase in muscle
367 strength, 3/ improvement in muscle elasticity. Finally, and perhaps more importantly, PWV
368 was increased at baseline, during CPET and during the recovery phase, as was the
369 augmentation index (Aix), all of which indicate more rigid arteries in the patients. Increased
370 stiffness may be responsible for greater recoil and therefore increased stress on the proximal
371 aorta, which has been associated with increased aortic root dilatation (ref) and may be related
372 to the altered vasodilator mechanism in response to acute exercise in MFS patients^{6,28}.
373 During the exercise program, PWV and Aix decreased. These effects may be beneficial in the
374 long term and are consistent with results from animal studies showing that exercise improves
375 aortic cellular structure and, in particular, arterial compliance^{11,12}. This beneficial effect
376 should be additive to the expected benefit associated with lower blood pressure resulting from
377 the lowering effect of training on blood pressure rise during exercise. Because of all these
378 indirect haemodynamic effects, one would expect that exercise would actually reduce the rate
379 of aortic root dilatation in this population. We did not see a decrease in aortic root dilatation
380 in our study, as has been reported in the mouse, but neither did we see an increase in
381 diameter. Obviously, our statistical power is too low: it took more than 4 years and more than
382 1000 subjects to suggest that sartan might possibly lead to a reduction in the rate of aortic root
383 dilatation²⁹.

384 This benefit can be expected with a minimum of risk: during the CPET and the
385 muscular exercise test (mET), the increase in blood pressure in MFS patients never exceeded
386 160 mmHg. It is important to note that, despite the limited increase in blood pressure, high
387 heart rates were achieved during the training session, as shown in Table 3 (e.g. an average of
388 85% of peak HR). This suggests that vigorous intensity exercise can be proposed without risk.
389 It is possible that the lower peak blood pressure observed during CPET at baseline (145 ± 19.5
390 vs. 188 ± 46.8 ; $p<0.001$) was related to the use of beta-blocker therapy in all patients.

391 In conclusion, MFS patients have altered QoL and exercise capacity, both of which
392 can be improved by supervised home exercise training. We also show that many
393 haemodynamic parameters are improved by training, which may translate into lower aortic
394 stress and therefore limit aortic root dilatation, although we were not able to show such an
395 effect in a short period of time in a limited population.

396

397 **Study limitations**

398 The program used during the training session was individualised and close monitoring of
399 heart rate and perceived exertion was carried out throughout the training period for all
400 patients. This takes time and may limit the reproducibility of the results obtained here.
401 However, a website is being set up to facilitate the adaptation of the sessions and to provide
402 all the necessary information to the patients. The size of the population is limited, but the
403 effect of training observed is impressive and unlikely to be the result of chance. Finally, the
404 population included was selected to be low-risk and the applicability of the results obtained in
405 higher-risk patients, who may benefit more from the training session, is unknown, particularly
406 because of the haemodynamic risk.

407

408 **Acknowledgments**

409 The authors dedicate this work to the patients who participated in the study and to all the
410 healthcare professionals in the Marfan Syndrome Reference Center in Hopital Bichat. This
411 study was presented at the European Days of the French Society of Cardiology in January
412 2022.

413

414 **Sources of Funding**

415 The study was sponsored by the Marfan Association, Multi-Fava, and Avenir Foundation.

416

417 **Disclosures**

418 The authors have no conflict of interest to report

419 **References**

- 420 1. Rahman MAE, Haase D, Rentzsch A, Olchvary J, Schäfers H-J, Henn W, Wagenpfeil
421 S, Abdul-Khaliq H. Left Ventricular Systolic Dysfunction in Asymptomatic Marfan
422 Syndrome Patients Is Related to the Severity of Gene Mutation: Insights from the
423 Novel Three Dimensional Speckle Tracking Echocardiography. *PLOS ONE*.
424 2015;10:e0124112. doi: 10.1371/journal.pone.0124112
- 425 2. Alpendurada F, Wong J, Kiotsekoglou A, Banya W, Child A, Prasad SK, Pennell DJ,
426 Mohiaddin RH. Evidence for Marfan cardiomyopathy. *Eur J Heart Fail*.
427 2010;12:1085-1091. doi: 10.1093/eurjhf/hfq127
- 428 3. Behan WMH, Longman C, Petty RKH, Comeglio P, Child AH, Boxer M, Foskett P,
429 Harriman DGF. Muscle fibrillin deficiency in Marfan's syndrome myopathy. *Journal*
430 *of Neurology, Neurosurgery & Psychiatry*. 2003;74:633-638. doi:
431 10.1136/jnnp.74.5.633
- 432 4. Giske L, Stanghelle JK, Rand-Hendrikssen S, Strom V, Wilhelmsen JE, Roe C.
433 Pulmonary function, working capacity and strength in young adults with Marfan
434 syndrome. *J Rehabil Med*. 2003;35:221-228. doi: 10.1080/16501970306095
- 435 5. Peters KF, Kong F, Horne R, Francomano CA, Biesecker BB. Living with Marfan
436 syndrome I. Perceptions of the condition. *Clinical Genetics*. 2001;60:273-282. doi:
437 10.1034/j.1399-0004.2001.600405.x
- 438 6. Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH,
439 Jondeau G, Evangelista A, Pyeritz RE. Marfan syndrome. *Nat Rev Dis Primers*.
440 2021;7:64. doi: 10.1038/s41572-021-00298-7
- 441 7. Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS.
442 Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database*
443 *Syst Rev*. 2016;2016:Cd001800. doi: 10.1002/14651858.CD001800.pub3
- 444 8. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet J-P, Corrado D,
445 Drezner JA, Halle M, et al. 2020 ESC Guidelines on sports cardiology and exercise in
446 patients with cardiovascular disease: The Task Force on sports cardiology and

- 447 exercise in patients with cardiovascular disease of the European Society of Cardiology
448 (ESC). *European Heart Journal*. 2021;42:17-96. doi: 10.1093/eurheartj/ehaa605
- 449 9. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT,
450 Corrà U, Cosyns B, Deaton C, et al. 2016 European Guidelines on cardiovascular
451 disease prevention in clinical practice: The Sixth Joint Task Force of the European
452 Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in
453 Clinical Practice (constituted by representatives of 10 societies and by invited
454 experts)Developed with the special contribution of the European Association for
455 Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016;37:2315-
456 2381. doi: 10.1093/eurheartj/ehw106
- 457 10. Judge DP, Dietz HC. Marfan's syndrome. *Lancet*. 2005;366:1965-1976. doi:
458 10.1016/s0140-6736(05)67789-6
- 459 11. Mas-Stachurska A, Siegert AM, Batlle M, Gorbenko del Blanco D, Meirelles T,
460 Rubies C, Bonorino F, Serra Peinado C, Bijmens B, Baudin J, et al. Cardiovascular
461 Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an
462 Animal Model. *Journal of the American Heart Association*. 2017;6:e006438. doi:
463 10.1161/JAHA.117.006438
- 464 12. Gibson C, Nielsen C, Alex R, Cooper K, Farney M, Gaufin D, Cui JZ, van Breemen
465 C, Broderick TL, Vallejo-Elias J, et al. Mild aerobic exercise blocks elastin fiber
466 fragmentation and aortic dilatation in a mouse model of Marfan syndrome associated
467 aortic aneurysm. *J Appl Physiol (1985)*. 2017;123:147-160. doi:
468 10.1152/jappphysiol.00132.2017
- 469 13. Jouini S, Milleron O, Eliahou L, Jondeau G, Vitiello D. Effects of a personalized
470 home-based training program among patients suffering from Marfan syndrome: a pilot
471 randomized and controlled study. *Intractable Rare Dis Res*. 2021;10:263-268. doi:
472 10.5582/irdr.2021.01080
- 473 14. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
474 Conceptual framework and item selection. *Med Care*. 1992;30:473-483.
- 475 15. Benninghoven D, Hamann D, von Kodolitsch Y, Rybczynski M, Lechinger J,
476 Schroeder F, Vogler M, Hoberg E. Inpatient rehabilitation for adult patients with
477 Marfan syndrome: an observational pilot study. *Orphanet J Rare Dis*. 2017;12:127.
478 doi: 10.1186/s13023-017-0679-0
- 479 16. Cheng A, Owens D. Marfan syndrome, inherited aortopathies and exercise: what is the
480 right answer? *Heart (British Cardiac Society)*. 2015;101:752-757. doi:
481 10.1136/heartjnl-2014-306440
- 482 17. Douard. Nouvelles recommandations pour la pratique du sport de compétition en cas
483 d'anomalie cardiovasculaire. *Archives des Maladies du Coeur et des Vaisseaux -*
484 *Pratique*. 2016;2016:27-30. doi: 10.1016/j.amcp.2016.01.010
- 485 18. Vorp DA, Schiro BJ, Ehrlich MP, Juvonen TS, Ergin MA, Griffith BP. Effect of
486 aneurysm on the tensile strength and biomechanical behavior of the ascending thoracic
487 aorta. *The Annals of Thoracic Surgery*. 2003;75:1210-1214. doi: 10.1016/s0003-
488 4975(02)04711-2
- 489 19. Haddad M, Stylianides G, Djaoui L, Dellal A, Chamari K. Session-RPE Method for
490 Training Load Monitoring: Validity, Ecological Usefulness, and Influencing Factors.
491 *Frontiers in Neuroscience*. 2017;11. doi: 10.3389/fnins.2017.00612
- 492 20. Foster C, Florhaug JA, Franklin J, Gottschall L, Hrovatin LA, Parker S, Doleshal P,
493 Dodge C. A new approach to monitoring exercise training. *J Strength Cond Res*.
494 2001;15:109-115.
- 495 21. Rand-Hendriksen S, Johansen H, Semb SO, Geiran O, Stanghelle JK, Finset A.
496 Health-related quality of life in Marfan syndrome: a cross-sectional study of Short

- 497 Form 36 in 84 adults with a verified diagnosis. *Genetics in Medicine: Official Journal*
498 *of the American College of Medical Genetics*. 2010;12:517-524. doi:
499 10.1097/GIM.0b013e3181ea4c1c
- 500 22. Vanem TT, Rand-Hendriksen S, Brunborg C, Geiran OR, Røe C. Health-related
501 quality of life in Marfan syndrome: a 10-year follow-up. *Health Qual Life Outcomes*.
502 2020;18:376. doi: 10.1186/s12955-020-01633-4
- 503 23. Hung C, Daub B, Black B, Welsh R, Quinney A, Haykowsky M. Exercise training
504 improves overall physical fitness and quality of life in older women with coronary
505 artery disease. *Chest*. 2004;126:1026-1031. doi: 10.1378/chest.126.4.1026
- 506 24. Moholdt TT, Amundsen BH, Rustad LA, Wahba A, Løvø KT, Gullikstad LR, Bye A,
507 Skogvoll E, Wisløff U, Slørdahl SA. Aerobic interval training versus continuous
508 moderate exercise after coronary artery bypass surgery: a randomized study of
509 cardiovascular effects and quality of life. *American Heart Journal*. 2009;158:1031-
510 1037. doi: 10.1016/j.ahj.2009.10.003
- 511 25. Giske L, Stanghelle JK, Rand-Hendrikssen S, Strøm V, Wilhelmsen J-E, Røe C.
512 Pulmonary function, working capacity and strength in young adults with Marfan
513 syndrome. *Journal of Rehabilitation Medicine*. 2003;35:221-228.
- 514 26. Percheron G, Fayet G, Ningler T, Le Parc J-M, Denot-Ledunois S, Leroy M, Raffestin
515 B, Jondeau G. Muscle strength and body composition in adult women with Marfan
516 syndrome. *Rheumatology*. 2007;46:957-962. doi: 10.1093/rheumatology/kel450
- 517 27. Tesch PA. Exercise performance and beta-blockade. *Sports Med*. 1985;2:389-412. doi:
518 10.2165/00007256-198502060-00002
- 519 28. Davis EC. Smooth muscle cell to elastic lamina connections in developing mouse
520 aorta. Role in aortic medial organization. *Lab Invest*. 1993;68:89-99.
- 521 29. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC, 3rd. Angiotensin II
522 blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med*.
523 2008;358:2787-2795. doi: 10.1056/NEJMoa0706585
- 524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546

547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565

Tables

Table 1 : Characteristics of MFS patients

Variables	MFS (n= 70)	H-S (n= 35)	P values
Age (years)	33.6 ± 10.2	31.2 ± 11.8	0.34
Height (cm)	179 ± 9.5	169 ± 7.85	<0.0001
Body weight (kg)	70.7 ± 15.2	64.1 ± 11.6	0.04
BMI	22 ± 6.4	21.9 ± 3.86	0.57
Body surface area (m ²)	1.88 ± 0.21	1.64 ± 0.14	0.0008
FM (kg)	21.4 ± 11.7	14.1 ± 7.96	0.003
MM (kg)	53.4 ± 47.6	47.6 ± 8.81	0.01
<i>Rest echocardiography</i>			
LVEF (%)	62.2 ± 7		
Aortic Ring (mm)	23.1 ± 2.6		
Aortic root (mm)	39.0 ± 4.7		
Tubular aorta (mm)	29.0 ± 4.1		
Aortic arch (mm)	21.1 ± 3.6		
Descending thoracic aorta (mm)	18.0 ± 2.6		
Abdominal aorta (mm)	15.2 ± 3.1		
LV GLS (%)	-19.6 ± 2.8		
Peak E/A	14.9 ± 33		
RV GLS (%)	-35.5 ± 16.3		
<i>Treatment</i>			
Beta-blockers (n=)	70		
Previous Bentall (n=)	7		

Other

Scoliosis (n=)	32
Sprained ankle (n=)	48
Pectus (n=)	27
Beighton score (mean)	5

566

567 MFS: Marfan Syndrome. H-S; Healthy Subjects. BMI: body mass index; E/A: left ventricle
568 early to late filling ratio; FM: fat mass; MM: muscle mass; LVEF: left ventricular ejection
569 fraction; LV GLS: left ventricle global longitudinal strain; RV GLS: global longitudinal
570 strain.

571 **Table 2: The quality of life and its evolution with training in MFS patients**

	H-S	MFS-C			MFS-T			p-value	
	baseline	baseline	post	Δ pre post	baseline	post	Δ pre post	Δ pre post	ANOVA 5 groups
Physical functioning	98±2	65±25	66.07±22.9	0.71±0.50	60.68±21.6	80.97±13.2	20.2±14.3 ^α	0.001	0.048
Social functioning	89±16	71±31	77.38±24.5	6.84±4.84	76.21±23.9	77.83±22.1	16.2±14	0.118	0.001
Role limitations: Physical	96±9	71±34	78.33±29.3	6.90±4.88	61.95±31.3	80.69±19.9	18.74±13.25	0.169	0.016
Role limitations: Emotional	90±13	88±31	83,33±34.7	-4.77±3.37	83.37±25.5	92.11±17.9	8.74±6.18	0.484	0.039
Mental health	77±12	73±21	70,43±21.4	-2.21±1.6	65.7±24.5	81.42±12.2	15.7±11.1	0.002	0.001
Energy / vitality	78±16	53±24	50,42±19.9	-2.08±1.47	48.81±20.0	75.01±16.8	26.19±18.51	0.001	0.002
Pain	94±8	69±29	64,56±21.4	-4.38±3.10	70.68±24.7	92.81±8.78	22.13±15.64	0.004	0.001
General health perceptions	83±14	51±16	55±20.2	3.57±2.52	55.65±18.9	70.56±16.9	14.91±10.54	0.009	0.041

572 H-S: healthy subjects. MFS-C: Marfan Controls. MFS-T : Marfan training. Δ pre post : difference between value at 3 months (post) and at
573 baseline (pre). At baseline MFS-C and MFS-T are significantly different from H-S for all parameters. After 3 months value changes were
574 significantly different in MFS-C and MFS-T.
575

576
577

Table 3 : Key parameters during training sessions for MFS patients

	Duration of training	HR peak	HR mean	RPE	BP1	BP2	BP3
Mean	987.5	145.2	116.8	6.41	123.1/76	132.2/78.7	126.3/74.9
SD	297.7	15.08	10.71	0.89	9.66/5.16	9.52/6.75	10.91/6.11

578
579
580
581
582
583
584

Duration of training: total training time during protocol. HR peak: peak heart rate reached during training sessions. HR means Mean heart rate during the entire training sessions. RPE: Rated Perceived Exertion Scale measured at the end of training session. BP1 Blood pressure before starting the training session. BP2: blood pressure at mid-session, BP3: blood pressure at the end of training session.

585

586 **Table 4: Cardiovascular and pulmonary effects of training in MFS patients**

Variables (Δ pre-post)	MFS-C		MFS-T		P values
LVEF (%)	-0.14	\pm 8.65	5.24	\pm 15.4	0.391
Cardiac Index (L/min/m ²)	0.05	\pm 0.83	0.05	\pm 0.92	0.990
Reflection coefficient (%)	-0.30	\pm 10.7	-12.4	\pm 14.5	0.020
Alx (%)	-3.10	\pm 12.9	-12.2	\pm 9.5	0.024
EI (cm)	0.13	\pm 1.52	1.89	\pm 1.99	0.009
PWV at rest (m/s)	-0.02	\pm 0.31	-0.45	\pm 0.45	0.011
PWV during squat (m/s)	0.60	\pm 1.02	-2.99	\pm 2.12	0.001
PWV post CPET (m/s)	0.95	\pm 0.75	-0.87	\pm 1.69	0.001
Systolic BP at rest (mmHg)	1.46	\pm 5.11	-2.20	\pm 6.13	0.070
Systolic BP during squat (mmHg)	3.50	\pm 6.42	-13.5	\pm 16.9	0.008
Systolic BP during CPET (mmHg)	12.9	\pm 30.7	-0.57	\pm 21.8	0.192
Systolic BP post CPET (mmHg)	5.36	\pm 4.89	-3.65	\pm 5.46	0.001
FEV1/FVC (%)	0.91	\pm 16.8	4.30	\pm 7.33	0.224
PEF 75-25 (%)	0.19	\pm 0.80	4.44	\pm 18.10	0.445

587

588 Δ : pre to post variation. Alx: augmentation index. BP: blood pressure. EI: Elasticity Index.

589 LVEF: left ventricular ejection fraction. MFS-C: Marfan control. MFS-T: Marfan training. PEF:

590 Peak expiratory flow. PWV: pulse wave velocity. FEV1/FVC%: Tiffeneau index.

591 **Figures legends :**

592

593 **Figure: 1 Flow chart.**

594

595 **Figure 2a : Peak oxygen consumption**

596 Peak oxygen consumption ($V\dot{V}O_{2peak}$) in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M). $\Delta 3M$ is the difference after 3 months compared to baseline. † $p < 0,05$ when compared to MFS-C Base and MFS-T Base. ‡ $p < 0,05$ vs. MFS-T Base and MFS-C Base and post. ⌘: The $\Delta 3M$ is significantly greater in MFS-T than in MFS-C ($p < 0,05$).

601

602 **Figure 2b Pulse wave velocity**

603 2b: Pulse wave velocity (PWV) after peak exercise. in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M). $\Delta 3M$ is the difference after 3 months compared to baseline. † $p < 0,05$ when compared to MFS-C Base and MFS-T Base. ‡ $p < 0,05$ vs. MFS-T Base and MFS-C Base and post. ⌘: The $\Delta 3M$ is significantly greater in MFS-T than in MFS-C ($p < 0,05$).

608

609 **Figure 2c Blood pressure during an isometric squat exercise**

610 Blood pressure (BP = SBP and DBP) is measured during an isometric squat exercise in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M). $\Delta 3M$ is the difference after 3 months compared to baseline. † $p < 0,05$ when compared to MFS-C Base and MFS-T Base. ‡ $p < 0,05$ vs. MFS-T Base and MFS-C Base and post. ⌘: The $\Delta 3M$ is significantly greater in MFS-T than in MFS-C ($p < 0,05$).

616

617 **Figure 2d Aortic root diameter**

618 Aortic root diameter is measured during an isometric squat exercise MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M). $\Delta 3M$ is the difference after 3 months compared to baseline. No significant difference were observed

622

623 **Figure 3a: One repetition maximum (1RM) test for lower limbs**

624 time of the one repetition maximum (1RM). in H-S (healthy subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at baseline (base) and after 3 months (3M). $\Delta 3M$ is the difference after 3 months compared to baseline. † $p < 0,05$ when compared to MFS-C Base and MFS-T Base. ‡ $p < 0,05$ vs. MFS-T Base and MFS-C Base and post. ⌘: The $\Delta 3M$ is significantly greater in MFS-T than in MFS-C ($p < 0,05$).

629

630

631

632 **Figure 3b: Elasticity Index (EI) assessed during vertical jump tests (CMJ-SJ)**

633 the elasticity index (EI) was assessed during vertical jump tests (CMJ-SJ) . in H-S (healthy
634 subjects), MFS-C (Marfan syndrome control), and MFS-T (Marfan syndrome training), at
635 baseline (base) and after 3 months (3M). $\Delta 3M$ is the difference after 3 months compared to
636 baseline. † $p < 0,05$ when compared to MFS-C Base and MFS-T Base. ‡ $p < 0,05$ vs. MFS-T
637 Base and MFS-C Base and post. ⌘: The $\Delta 3M$ is significantly greater in MFS-T than in MFS-C
638 ($p < 0,05$).

Figure 1: Flow chart of study inclusion criteria and design




Figure 2

Figure 2a: Maximal oxygen consumption




Figure 2b: pulse wave velocity (PWV) after maximal exercise ok




Figure 2c: Blood pressure during an isometric squat exercise ok




Figure 2d: Aortic root diameter ok




FIGURE 3

Figure 3a : First one-repetition maximum (1RM) test for lower limbs




Figure 3b: Elasticity Index (EI) assessed during vertical jump tests (CMJ-SJ)

